Min Ningning, Wei Yufan, Zheng Yiqiong, Li Xiru
School of Medicine, Nankai University, Tianjin, China.
Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, China.
Gland Surg. 2021 Sep;10(9):2815-2831. doi: 10.21037/gs-21-441.
To provide a reference for clinical work and guide the decision-making of healthcare providers and end-users, we systematically reviewed the development, validation and classification of classical prognostic models for breast cancer.
Patients suffering from breast cancer have different prognosis for its high heterogeneity. Accurate prognosis prediction and risk stratification for breast cancer are crucial for individualized treatment. There is a lack of systematic summary of breast cancer prognostic models.
We conducted a PubMed search with keywords "breast neoplasm", "prognostic model", "recurrence" and "metastasis", and screened the retrieved publications at three levels: title, abstract and full text. We identified the articles presented the development and/or validation of models based on clinicopathological factors, genomics, and machine learning (ML) methods to predict survival and/or benefits of adjuvant therapy in female breast cancer patients.
Combining prognostic-related variables with long-term clinical outcomes, researchers have developed a series of prognostic models based on clinicopathological parameters, genomic assays, and medical figures. The discrimination, calibration, overall performance, and clinical usefulness were validated by internal and/or external verifications. Clinicopathological models integrated the clinical parameters, including tumor size, histological grade, lymph node status, hormone receptor status to provide prognostic information for patients and doctors. Gene-expression assays deeply revealed the molecular heterogeneity of breast cancer, some of which have been cited by AJCC and National Comprehensive Cancer Network (NCCN) guidelines. In addition, the models based on the ML methods provided more detailed information for prognosis prediction by increasing the data dimension. Combined models incorporating clinical variables and genomics information are still required to be developed as the focus of further researches.
为临床工作提供参考并指导医疗服务提供者和终端用户的决策,我们系统回顾了乳腺癌经典预后模型的开发、验证和分类。
乳腺癌患者因其高度异质性而具有不同的预后。准确的乳腺癌预后预测和风险分层对于个体化治疗至关重要。目前缺乏对乳腺癌预后模型的系统总结。
我们在PubMed上以“乳腺肿瘤”“预后模型”“复发”和“转移”为关键词进行检索,并在标题、摘要和全文三个层面筛选检索到的出版物。我们确定了基于临床病理因素、基因组学和机器学习(ML)方法展示模型开发和/或验证的文章,以预测女性乳腺癌患者的生存和/或辅助治疗的获益情况。
研究人员将预后相关变量与长期临床结果相结合,基于临床病理参数、基因组检测和医学数据开发了一系列预后模型。通过内部和/或外部验证对其区分度、校准度、整体性能和临床实用性进行了验证。临床病理模型整合了包括肿瘤大小、组织学分级、淋巴结状态、激素受体状态等临床参数,为患者和医生提供预后信息。基因表达检测深入揭示了乳腺癌的分子异质性,其中一些已被美国癌症联合委员会(AJCC)和美国国立综合癌症网络(NCCN)指南引用。此外,基于ML方法的模型通过增加数据维度为预后预测提供了更详细的信息。作为进一步研究的重点,仍需要开发结合临床变量和基因组学信息的联合模型。